PL1675954T3 - Kwasy nukleinowe użyteczne do wywoływania śmiertelności komórek nowotworowych - Google Patents

Kwasy nukleinowe użyteczne do wywoływania śmiertelności komórek nowotworowych

Info

Publication number
PL1675954T3
PL1675954T3 PL04817274T PL04817274T PL1675954T3 PL 1675954 T3 PL1675954 T3 PL 1675954T3 PL 04817274 T PL04817274 T PL 04817274T PL 04817274 T PL04817274 T PL 04817274T PL 1675954 T3 PL1675954 T3 PL 1675954T3
Authority
PL
Poland
Prior art keywords
nucleic acids
tumor cell
acids useful
cell lethality
triggering tumor
Prior art date
Application number
PL04817274T
Other languages
English (en)
Polish (pl)
Inventor
Marie Dutreix
Jian-Sheng Sun
Original Assignee
Inst Curie
Centre Nat Rech Scient
Museum Nat Dhistoire Naturelle
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Curie, Centre Nat Rech Scient, Museum Nat Dhistoire Naturelle, Inst Nat Sante Rech Med filed Critical Inst Curie
Publication of PL1675954T3 publication Critical patent/PL1675954T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/13—Decoys
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
PL04817274T 2003-10-24 2004-10-25 Kwasy nukleinowe użyteczne do wywoływania śmiertelności komórek nowotworowych PL1675954T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03292666A EP1526177A1 (en) 2003-10-24 2003-10-24 Nucleic acids useful for triggering tumor cell lethality
PCT/EP2004/012857 WO2005040378A1 (en) 2003-10-24 2004-10-25 Nucleic acids useful for triggering tumor cell lethality
EP04817274A EP1675954B1 (en) 2003-10-24 2004-10-25 Nucleic acids useful for triggering tumor cell lethality

Publications (1)

Publication Number Publication Date
PL1675954T3 true PL1675954T3 (pl) 2011-04-29

Family

ID=34384721

Family Applications (1)

Application Number Title Priority Date Filing Date
PL04817274T PL1675954T3 (pl) 2003-10-24 2004-10-25 Kwasy nukleinowe użyteczne do wywoływania śmiertelności komórek nowotworowych

Country Status (15)

Country Link
US (1) US7595302B2 (https=)
EP (2) EP1526177A1 (https=)
JP (2) JP4743789B2 (https=)
CN (1) CN1871350B (https=)
AT (1) ATE485375T1 (https=)
AU (1) AU2004284228B2 (https=)
CA (1) CA2542942C (https=)
CY (1) CY1111060T1 (https=)
DE (1) DE602004029699D1 (https=)
DK (1) DK1675954T3 (https=)
ES (1) ES2354359T3 (https=)
PL (1) PL1675954T3 (https=)
PT (1) PT1675954E (https=)
SI (1) SI1675954T1 (https=)
WO (1) WO2005040378A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7476729B2 (en) * 2003-10-24 2009-01-13 Institut Curie Dbait and uses thereof
EP1944369A1 (en) * 2007-01-12 2008-07-16 The Centre National de la Recherche Scientifique Dbait and its standalone uses thereof
WO2009149921A2 (en) * 2008-06-11 2009-12-17 Bionucleon S.R.L. Inhibition of hrp-3 using modified oligonucleotides
US9205099B2 (en) 2010-06-22 2015-12-08 Dna Therapeutics Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
AU2015202211B2 (en) * 2010-06-22 2016-09-01 Centre National De La Recherche Scientifique Optimized in vivo delivery system with endosomolytic agents for nucleic acid conjugates
EP2527440A1 (en) * 2011-05-27 2012-11-28 Institut Curie Cancer treatment by combining DNA molecules mimicking double strand breaks with hyperthermia
AU2014316676B2 (en) * 2013-09-04 2020-07-23 Csir Site-specific nuclease single-cell assay targeting gene regulatory elements to silence gene expression
EP3919621A1 (en) * 2014-06-23 2021-12-08 The General Hospital Corporation Genomewide unbiased identification of dsbs evaluated by sequencing (guide-seq)
JP6457696B2 (ja) 2015-07-23 2019-01-23 アンスティテュ・キュリＩｎｓｔｉｔｕｔ Ｃｕｒｉｅ 癌を処置するためのＤｂａｉｔ分子とＰＡＲＰインヒビターとの組合せの使用
US10821128B2 (en) * 2016-03-01 2020-11-03 Onxeo Treatment of cancer by systemic administration of Dbait molecules
WO2017186882A1 (en) 2016-04-29 2017-11-02 Onxeo A method of predicting a response to an anti-tumor treatment by means of signal interfering dna molecules
US10876116B2 (en) 2016-07-15 2020-12-29 The Board Of Regents Of The University Of Oklahoma Anti-ARID3a treatments for inflammatory disorders
WO2018162439A1 (en) 2017-03-08 2018-09-13 Onxeo New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule
EP3461488A1 (en) 2017-09-27 2019-04-03 Onxeo Combination of a dbait molecule and a hdac inhibitor for treating cancer
CN108261548B (zh) * 2018-01-10 2020-04-10 浙江大学 一种纳米复合物及其制备方法和应用
KR20200130856A (ko) 2018-03-13 2020-11-20 옹쎄오 암 치료에서 획득한 내성에 대한 디베이트 분자
CA3097044A1 (en) 2018-04-17 2019-10-24 The General Hospital Corporation Sensitive in vitro assays for substrate preferences and sites of nucleic acid binding, modifying, and cleaving agents
WO2020127965A1 (en) 2018-12-21 2020-06-25 Onxeo New conjugated nucleic acid molecules and their uses
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
TW202210633A (zh) 2020-06-05 2022-03-16 法商昂席歐公司 用於治療癌症之dbait分子與kras抑制劑的組合
AR122644A1 (es) 2020-06-19 2022-09-28 Onxeo Nuevas moléculas de ácido nucleico conjugado y sus usos
JP2025500922A (ja) 2021-12-16 2025-01-15 ヴァレリオ・セラピューティクス 新規のコンジュゲートされた核酸分子及びその使用
WO2024240858A1 (en) 2023-05-23 2024-11-28 Valerio Therapeutics Protac molecules directed against dna damage repair system and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ255028A (en) * 1992-07-02 1997-03-24 Hybridon Inc Antisense oligonucleotides resistant to nucleolytic degradation
US6441158B1 (en) * 1997-12-31 2002-08-27 Medical College Of Georgia Research Institute, Inc. Oligomers that bind to ku protein
EP0978561A1 (en) * 1998-08-07 2000-02-09 Hoechst Marion Roussel Deutschland GmbH Antisense oligonucleotides for the inhibition of VEGF expression
AU2002241952A1 (en) * 2001-01-22 2002-07-30 Genta Incorporated Cell-proliferative disorder treatments using cre decoy oligomers, bcl-2 antisense and hybrid oligomers
CA2476468A1 (en) 2002-02-13 2003-08-21 Medbridge, Inc. Protein carrier system for therapeutic oligonucleotides
AU2003207708A1 (en) 2002-02-20 2003-09-09 Sirna Therapeutics, Inc. Rna interference mediated inhibition of map kinase genes

Also Published As

Publication number Publication date
WO2005040378A1 (en) 2005-05-06
CN1871350B (zh) 2014-10-15
DK1675954T3 (da) 2011-01-10
EP1675954A1 (en) 2006-07-05
CY1111060T1 (el) 2015-06-11
AU2004284228B2 (en) 2010-04-08
JP4743789B2 (ja) 2011-08-10
SI1675954T1 (sl) 2011-01-31
ATE485375T1 (de) 2010-11-15
ES2354359T3 (es) 2011-03-14
CA2542942C (en) 2014-04-29
JP2007510405A (ja) 2007-04-26
US20070197458A1 (en) 2007-08-23
JP2011126897A (ja) 2011-06-30
PT1675954E (pt) 2010-12-27
EP1526177A1 (en) 2005-04-27
US7595302B2 (en) 2009-09-29
JP5662822B2 (ja) 2015-02-04
DE602004029699D1 (de) 2010-12-02
CN1871350A (zh) 2006-11-29
CA2542942A1 (en) 2005-05-06
AU2004284228A1 (en) 2005-05-06
EP1675954B1 (en) 2010-10-20

Similar Documents

Publication Publication Date Title
PL1675954T3 (pl) Kwasy nukleinowe użyteczne do wywoływania śmiertelności komórek nowotworowych
EP2270042A3 (en) KDR peptides and vaccines comprising the same
EP2003196A3 (en) Compositions and methods for treating and diagnosing cancer
HRP20070012A2 (hr) Imunostimulatorski oligonukleotidni multimeri
IL190796A (en) Composition containing nucleic acid encoded by anti-osteoclastogenic protein
EP2679246A3 (en) Novel therapeutical tools and methods for treating blindness
WO2004037977A3 (en) Use of chimeric nucleases to stimulate gene targeting
MY131964A (en) 2-amino-2-alkyl-5 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
TW200502385A (en) Modulation of forkhead box o1a expression
TR200202196T2 (tr) Homolog yeniden kombine etmeyi iyileştirme yöntemleri
WO2006050211A3 (en) Peripherally delivered glutamic acid decarboxylase gene therapy for spinal cord injury pain
WO2006018836A3 (en) Nucleic acid constructs and cells, and methods utilizing same for modifying the electrophysiological function of excitable tissues
AR051350A1 (es) Vacuna de glucoproteina mucinosa (muc-1)
AR054526A1 (es) Metodo para tartar pacientes con una vacuna de glicoproteina mucinosa (muc-1)
WO2004013313A3 (en) Antisense nucleic acids
WO2003092736A3 (en) Peptide nucleic acid conjugates with transporter peptides
WO2005007098A3 (en) Nucleic acid therapy to enhance cartilage repair
WO2003090778A3 (en) Dna vaccine combined with an inducer of tumor cell apoptosis
DK1507863T3 (da) Plasmidstabilisering in vivo
AU1248602A (en) Formulations comprising dextrin polymers in combination with sugars for the delivery of nucleic acids
WO2002068629A3 (en) Dna constructs for cytoplasmic and mithochondrial expression and methods of making and using same
WO2004011623A3 (en) Antisense modulation of ptpra expression
WO2002022557A3 (en) 2-amino-2-alkyl-4 heptenoic and heptynoic acid derivatives useful as nitric oxide synthase inhibitors
WO2005094282A3 (en) Combination therapy comprising cloretazinetm
WO2004003153A3 (en) Live replicating spumavirus vector